Stock Scorecard
Stock Summary for Revolution Medicines Inc (RVMD) - $97.78 as of 1/26/2026 8:39:46 PM EST
Total Score
6 out of 30
Safety Score
39 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RVMD
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RVMD
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RVMD
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for RVMD
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for RVMD (39 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 7 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for RVMD
Financial Details for RVMD
Company Overview |
|
|---|---|
| Ticker | RVMD |
| Company Name | Revolution Medicines Inc |
| Country | N/A |
| Description | Revolution Medicines, Inc. is a pioneering clinical-stage oncology firm based in Redwood City, California, focused on developing transformative therapies for RAS-addicted cancers. By leveraging precision medicine to confront previously "undruggable" cancer drivers, the company addresses vital unmet medical needs in oncology. With a strong pipeline of innovative treatments and strategic partnerships with industry leaders, Revolution Medicines is well-positioned to enhance patient outcomes, offering an attractive investment prospect for institutional investors in next-generation cancer therapeutics. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 2/25/2026 |
Stock Price History |
|
| Last Day Price | 97.78 |
| Price 4 Years Ago | 23.82 |
| Last Day Price Updated | 1/26/2026 8:39:46 PM EST |
| Last Day Volume | 10,170,050 |
| Average Daily Volume | 4,541,351 |
| 52-Week High | 124.49 |
| 52-Week Low | 29.17 |
| Last Price to 52 Week Low | 235.21% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 25.93 |
| Sector PE | 128.28 |
| 5-Year Average PE | -11.41 |
| Free Cash Flow Ratio | 87.30 |
| Industry Free Cash Flow Ratio | 32.34 |
| Sector Free Cash Flow Ratio | 35.08 |
| Current Ratio Most Recent Quarter | 8.05 |
| Total Cash Per Share | 1.12 |
| Book Value Per Share Most Recent Quarter | 8.42 |
| Price to Book Ratio | 14.07 |
| Industry Price to Book Ratio | 56.10 |
| Sector Price to Book Ratio | 21.76 |
| Price to Sales Ratio Twelve Trailing Months | 9,035.10 |
| Industry Price to Sales Ratio Twelve Trailing Months | 58.10 |
| Sector Price to Sales Ratio Twelve Trailing Months | 28.33 |
| Analyst Buy Ratings | 16 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 193,320,000 |
| Market Capitalization | 18,902,829,600 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -37.52% |
| Reported EPS 12 Trailing Months | -5.19 |
| Reported EPS Past Year | -4.05 |
| Reported EPS Prior Year | -3.57 |
| Net Income Twelve Trailing Months | -960,978,000 |
| Net Income Past Year | -600,093,000 |
| Net Income Prior Year | -436,367,000 |
| Quarterly Revenue Growth YOY | -95.20% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 217,442,000 |
| Total Cash Past Year | 543,064,000 |
| Total Cash Prior Year | 696,148,000 |
| Net Cash Position Most Recent Quarter | 217,442,000 |
| Net Cash Position Past Year | 543,064,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 2,265,204,000 |
| Total Stockholder Equity Prior Year | 1,826,194,000 |
| Total Stockholder Equity Most Recent Quarter | 1,596,904,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -777,080,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -4.02 |
| Free Cash Flow Past Year | -567,744,000 |
| Free Cash Flow Prior Year | -358,301,000 |
Options |
|
| Put/Call Ratio | 0.18 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.99 |
| RSI | 0.00 |
| 50-Day SMA | 50.08 |
| 150-Day SMA | 39.41 |
| 200-Day SMA | 35.04 |
System |
|
| Modified | 1/24/2026 7:15:06 AM EST |